登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C8H12N4O5
化学文摘社编号:
分子量:
244.20
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
ribavirin
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
InChI
1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChI key
IWUCXVSUMQZMFG-AFCXAGJDSA-N
Gene Information
human ... IMPDH1(3614)
General description
嘌呤核苷酸生物合成中咪唑核苷酸中间体的类似物。
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Ribavirin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂，但也有实验证据支持许多其他作用机制。
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 利巴韦林
signalword
Danger
hcodes
pcodes
Hazard Classifications
Muta. 2 - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Fred Poordad et al.
The New England journal of medicine, 370(21), 1973-1982 (2014-04-15)
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir
Eric Druyts et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 56(7), 961-967 (2012-12-18)
A systematic review and meta-analysis were conducted to examine the efficacy and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) in children and adolescents with chronic hepatitis C virus (HCV). Medline, Embase, and Cochrane Central Register
Michael Manns et al.
Lancet (London, England), 384(9954), 1597-1605 (2014-08-01)
An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus asunaprevir (NS3 protease inhibitor) in patients with genotype 1b infection
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0000377-2EA | 04061837568411 |